SAT-330 Preclinical Screen of Patient CRPC Tumors Shows Sensitivity to Bromodomain Inhibitors Includes AR-null and Neuroendocrine Disease

Castration-resistant prostate cancer (CRPC) remains a lethal disease despite the introduction of second generation androgen receptor (AR) directed therapies. Resistance to AR directed therapies, such as abiraterone and enzalutamide, emerges through diverse alterations in the AR pathway or transition...

Full description

Saved in:
Bibliographic Details
Published in:J Endocr Soc
Main Authors: Risbridger, Gail, Ashikari, Daisaku, Lawrence, Mitchell, Obinata, Daisuke, Wang, Hong, Sandhu, Shahneen, Azad, Arun, Taylor, Renea
Format: Artigo
Language:Inglês
Published: Endocrine Society 2019
Subjects:
Tumor Biology
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6551945/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SAT-330
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items